CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ShangPharma Corp (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ShangPharma Corp (ADR)
No. 5 Building, 998 Halei Road
Zhangjiang Hi-Tech Park, Pudong New Area
Phone: +86 2151320088p:+86 2151320088 SHANGHAI, SHA  201203  China Ticker: SHPSHP
This company was Merged or Acquired on 3/28/2013.
This company ceased filing statements with the SEC on 4/15/2013.
Merged or Acquired by ShangPharma Parent Limited.
This company is no longer actively traded on any major stock exchange.
Business Summary
ShangPharma Corporation (ShangPharma) is a China-based holding company. The Company is a pharmaceutical and biotechnology research and development (R&D) outsourcing company. It provides a range of high-quality, integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies. Its services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. It has a diversified and loyal global customer base. In March 2013, the Company completed the merger contemplated by the previously announced Agreement and Plan of Merger (the Merger Agreement), by and among the Company, ShangPharma Holdings Limited (Holdings), ShangPharma Parent Limited (Parent) and ShangPharma Merger Sub Limited (Merger Sub). As a result of the merger, the Company became a wholly owned subsidiary of Parent.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201212/31/2011YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer XinHui 40 1/1/2002 1/1/2002
Chief Financial Officer WilliamDai 48 1/10/2011 1/10/2011
Vice President - Finance and Investor Relations LanXie 39 8/1/2011 11/1/2007
4 additional Officers and Directors records available in full report.

Business Names
Business Name
ChemExplorer Company Limited
Chengdu Chempartner Co., Ltd.
China Gateway Life Science (Holdings) Limited
9 additional Business Names available in full report.

General Information
Number of Employees: 2,076 (As of 12/31/2011)
Outstanding Shares: 335,000,510 (As of 12/14/2012)
Stock Exchange: NYSE
Fax Number: +86 2151320110


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023